802 related articles for article (PubMed ID: 25646110)
1. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
Falit BP; Singh SC; Brennan TA
Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
[TBL] [Abstract][Full Text] [Related]
2. The complexities of biosimilars and the regulatory approval process.
Lucio S
Am J Manag Care; 2018 Jun; 24(11 Suppl):S231-S236. PubMed ID: 29957908
[TBL] [Abstract][Full Text] [Related]
3. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
[TBL] [Abstract][Full Text] [Related]
4. An unofficial legislative history of the Biologics Price Competition and Innovation Act of 2009.
Carver KH; Elikan J; Lietzan E
Food Drug Law J; 2010; 65(4):671-818, ii. PubMed ID: 24479247
[TBL] [Abstract][Full Text] [Related]
5. Comparing Onset of Biosimilar Versus Generic Competition in the United States.
Beall RF; Ronksley PE; Wick J; Darrow JJ; Sarpatwari A; Kesselheim AS
Clin Pharmacol Ther; 2020 Dec; 108(6):1308-1314. PubMed ID: 32621540
[TBL] [Abstract][Full Text] [Related]
6. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
Grabowski HG; Guha R; Salgado M
Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
[TBL] [Abstract][Full Text] [Related]
7. Business of biosimilars - 14th annual conference (October 15-17, 2013 - Boston, Massachusetts, USA).
Bourgoin A
Drugs Today (Barc); 2013 Dec; 49(12):799-801. PubMed ID: 24524098
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars in the United States: Emerging Issues in Litigation.
Wong AY; Rumore MM; Chan AW
BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
[TBL] [Abstract][Full Text] [Related]
9. How drug life-cycle management patent strategies may impact formulary management.
Berger J; Dunn JD; Johnson MM; Karst KR; Shear WC
Am J Manag Care; 2016 Oct; 22(16 Suppl):S487-S495. PubMed ID: 28719222
[TBL] [Abstract][Full Text] [Related]
10. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
[TBL] [Abstract][Full Text] [Related]
11. Follow-on biologics: data exclusivity and the balance between innovation and competition.
Grabowski H
Nat Rev Drug Discov; 2008 Jun; 7(6):479-88. PubMed ID: 18469828
[TBL] [Abstract][Full Text] [Related]
12. Hot Topics in Primary Care: Demystifying the Differences: Follow-on Biologics, Biosimilars, and Generics.
Wright EE; Blevins TC; Reed B; Pollom RD
J Fam Pract; 2017 Apr; 66(4 Suppl):S22-S27. PubMed ID: 28375404
[TBL] [Abstract][Full Text] [Related]
13. The economic implications of biosimilars.
Singh SC; Bagnato KM
Am J Manag Care; 2015 Dec; 21(16 Suppl):s331-40. PubMed ID: 26788809
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars: How Can Payers Get Long-Term Savings?
Mestre-Ferrandiz J; Towse A; Berdud M
Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars: impact of differences with Hatch-Waxman.
Kowalchyk K; Crowley-Weber C
Pharm Pat Anal; 2013 Jan; 2(1):29-37. PubMed ID: 24236968
[TBL] [Abstract][Full Text] [Related]
16. Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018.
Rome BN; Lee CC; Kesselheim AS
Clin Pharmacol Ther; 2021 Feb; 109(2):367-371. PubMed ID: 32654122
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars: The US Regulatory Framework.
Christl LA; Woodcock J; Kozlowski S
Annu Rev Med; 2017 Jan; 68():243-254. PubMed ID: 27813877
[TBL] [Abstract][Full Text] [Related]
18. Optimizing use and addressing challenges to uptake of biosimilars.
Leber MB
Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
[TBL] [Abstract][Full Text] [Related]
19. The economics of biosimilars.
Blackstone EA; Joseph PF
Am Health Drug Benefits; 2013 Sep; 6(8):469-78. PubMed ID: 24991376
[TBL] [Abstract][Full Text] [Related]
20. Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose it.
Mehr SR
J Manag Care Spec Pharm; 2024 Jun; 30(6):600-603. PubMed ID: 38824633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]